Skip to main content

Springer Timothy A's Form 4 filing

Cartesian Therapeutics, Inc. (RNAC) · filed Mar 28, 2024

Accession no.
0001453687-24-000050
Filed
Mar 28, 2024
Trade date
Jan 17-Mar 18, 2024
Filing delay
71 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 10 non-derivative transactions. Open-market purchases total $11.4K. It was filed 71 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Springer Timothy ACIK 0001055624Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 17, 2024Common StockPPurchaseAcquired+800$0.69+$55287,218Indirect
Feb 6, 2024Common StockPPurchaseAcquired+800$0.65+$52088,018Indirect
Feb 7, 2024Common StockPPurchaseAcquired+2,400$0.66F1+$1,58490,418Indirect
Mar 8, 2024Common StockPPurchaseAcquired+4,800$0.66F2+$3,16895,218Indirect
Mar 11, 2024Common StockPPurchaseAcquired+1,200$0.65F3+$78096,418Indirect
Mar 12, 2024Common StockPPurchaseAcquired+1,200$0.61F4+$73297,618Indirect
Mar 13, 2024Common StockPPurchaseAcquired+3,200$0.58F5+$1,856100,818Indirect
Mar 14, 2024Common StockPPurchaseAcquired+2,000$0.53F6+$1,060102,818Indirect
Mar 15, 2024Common StockPPurchaseAcquired+1,200$0.56+$672104,018Indirect
Mar 18, 2024Common StockPPurchaseAcquired+800$0.61+$488104,818Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.66. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.61 to $0.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.58 to $0.59. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F6

The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.52 to $0.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)